Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Graft Versus Host Disease (GVHD) Market

Graft Versus Host Disease (GVHD) Market Trends

Report ID: GMI8768
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Graft Versus Host Disease Market Trends

The surge in market growth is driven by escalating rates of bone marrow or hematopoietic stem cell treatments, coupled with a growing incidence of GVHD, prompting the development of innovative therapies. To address the global demand for novel treatments, pharmaceutical companies heavily investing to intensify research endeavors, expanding their product portfolios.
For instance, in December 2021, the U.S. (FDA) approved Orencia for preventing aGVHD when used alongside specific immunosuppressants. This approval is extended to adult and pediatric patients aged two years and older undergoing HCT from an unrelated donor. The approval aimed to drive market growth by introducing effective treatment options to address the global demand for rare disease management.
Similarly, Equillium Inc.'s completion of an End-of-Phase 1 meeting with the US FDA for itolizumab in aGvHD treatment presents promising prospects. Positive clinical trial outcomes are expected to introduce new treatments.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Graft versus host disease (GVHD) industry size was USD 2.5 billion in 2023 and is expected to record USD 5.1 billion by 2032, due to the increasing prevalence of hematological disorders and malignancies necessitating hematopoietic stem cell transplantation (HSCT).

The hospital pharmacies distribution channel segment recorded 48.4% revenue share in 2023 and is expected to reach USD 2.4 billion by end of 2032, due to their pivotal role in providing immediate access to specialized medications and therapies.

North America graft versus host disease industry size was anticipated to reach USD 2.1 billion by 2032, attributed to its robust healthcare infrastructure, growing R&D activities, and escalating transplant rates.

Some of the leading GVHD firms are Astellas Pharma Inc., Bristol Myers Squibb, ElsaLys Biotech SA, Incyte Corporation, Johnson & Johnson Services, Inc., Kiadis Pharma, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., and Mesoblast Ltd.